CVS Health Lays out Changes That May Save some Customers Money

NYSE:CVS   CVS Health Corporation
CVS Health is introducing changes to how its prescription drug pricing model works, and that could lead to some savings for customers starting next year.

The health care giant said Tuesday that it will roll out a new reimbursement model designed to make costs more predictable at the drugstore counter. The company will start offering it next year to some third-party cash discount card administrators.

Cash discount cards like those offered by GoodRx can give customers a price break on out-of-pocket costs for some prescriptions, depending on the person’s coverage and the drug.

CVS Health drugstores will start using the company’s new Cost Vantage model more broadly in 2025. It is designed to make drug costs more transparent. It involves a formula based on the cost of the drug, a set markup and then a fee for filling the prescription.

CVS Health runs one of the nation’s largest drugstore chains and a large pharmacy benefit management business that operates prescription drug coverage for big clients like insurers and employers.

It also sells health insurance through its Aetna arm, and the company has been providing a growing amount of care through its drugstores and clinics.

The company also announced on Tuesday a 10% hike in its quarterly dividend and laid out its forecast for next year. CVS Health expects adjusted earnings of at least $8.50 per share. It also forecasts total revenue of at least $366 billion.

Analysts expect earnings of $8.51 per share on $344.5 billion in revenue, according to FactSet.

Price Momentum
CVS is trading near the bottom of its 52-week range and near its 200-day simple moving average. Investors have been pushing the share price lower, but the stock might be losing some downward momentum. This is a neutral sign for the stock's future value.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play!

2) Text Message Notifications:

3) Telegram:

4) Follow Us on our Social Networks

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.